TNF and psoriasis: TNF-α inhibitors, including etanercept, infliximab, and adalimumab, represent the first class of biologics employed in psoriasis treatment, exhibiting substantial success in diminishing psoriatic plaques and enhancing quality of life (Megna et al. 2022; Nikam et al. 2023; Ferrara et al. 2024).